



# Supplementary Material: Low Spike Antibody Levels and Impaired BA.4/5 Neutralization in Patients with Multiple Myeloma or Waldenstrom's Macroglobulinemia after BNT162b2 Booster Vaccination

Margherita Rosati, Evangelos Terpos, Jenifer Bear, Robert Burns, Santhi Devasundaram, Ioannis Ntanas-Stathopoulos, Maria Gavriatopoulou, Efsthios Kastiris, Meletios-Athanasios Dimopoulos, George N. Pavlakakis and Barbara K. Felber



**Figure S1.** Comparison of anti-Spike and anti-Spike-RBD Ab. **(A-D)** Comparison of antibody responses to trimeric Spike and Spike-RBD of **(A)** WA1, **(B)** Delta and the Omicron variants **(C)** BA.1 and **(D)** BA.2 in HCW and the different patient cohorts measured after the 3<sup>rd</sup> dose (month10). The number of samples analyzed; fold difference of antibody titers to Spike and Spike-RBD; the number samples with positive Spike-RBD titers (> threshold 50) and with titers >3000, the threshold applied for sample selection for NAb assay (Fig. 4H), are given.



**Figure S2.** Comparison of NAb using the WA1 pseudotyped neutralization assay and the cPass SARS-CoV2 NAb assay. The data from the cPass assay (x axis) were grouped according to the % neutralization. This comparison shows an overall agreement among the assays and further shows that the pseudotype NAb assay has the power to better distinguish the neutralization capability.